Carboxylesterases Expressed in Human Colon Tumor Tissue and Their Role in CPT-11 Hydrolysis

Clinical Cancer Research

Volumn 9, Issue 13, 2003, Pages 4983-4991

  Sanghani, Sonal P ^a   Quinney, Sara K ^b   Fredenburg, Tyler B ^a   Sun, Zejin ^a   Davis, Wilhelmina I ^a   Murry, Daryl J ^b   Cummings, Oscar W ^a   Seitz, David E ^a   Bosron, William F ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; DNA TOPOISOMERASE; HYMECROMONE SULFATE; IRINOTECAN;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOAVAILABILITY; CARBOXYLESTERASE 1A1 GENE; CARBOXYLESTERASE 2 GENE; CARBOXYLESTERASE 3 GENE; COLON TUMOR; DIARRHEA; DRUG EFFECT; GEL ELECTROPHORESIS; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; HYDROLYSIS; LEUKOPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; TOPOISOMERASE 1 GENE;

BLOTTING, NORTHERN; BLOTTING, WESTERN; BRAIN; CAMPTOTHECIN; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CELL LINE, TUMOR; COLON; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; HYDROLASES; HYDROLYSIS; LIVER; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; UMBELLIFERONES;

EID: 0142157104     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Holen, K. D., and Saltz, L. B. New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. Lancet Oncol., 2: 290-297, 2001.
2. Jansen, W. J., Zwart, B., Hulscher, S. T., Giaccone, G., Pinedo, H. M., and Boven, E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int. J. Cancer, 70: 335-340, 1997.
3. Ark-Otte, J., Kedde, M. A., van der Vijgh, W. J., Dingemans, A. M., Jansen, W. J., Pinedo, H. M., Boven, E., and Giaccone, G. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br. J. Cancer. 77: 2171-2176, 1998.
4. Mathijssen, R. H., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., and Sparreboom, A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res., 7: 2182-2194, 2001.
5. Canal, P., Gay, C., Dezeuze, A., Douillard, J. Y., Bugat, R., Brunet, R., Adenis, A., Herait, P., Lokiec, F., and Mathieu-Boue, A. Pharmacokinetics and pharmacodynamics of irinotecan during a Phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol., 14: 2688-2695, 1996.
6. Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson, M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K., Compton, L. D., Miller, L. L., Baker, D. S., Pesheck, C. V., and Lord, R. S., III. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab. Dispos., 28: 423-433, 2000.
7. Hecht, J. R. Gastrointestinal toxicity or irinotecan. Oncology (Huntingt.), 12: 72-78, 1998.
8. Satoh, T., Hosokawa, M., Atsumi, R., Suzuki, W., Hakusui, H., and Nagai, E. Metabolic activation of CPT-11,7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharm. Bull., 17: 662-664, 1994.
9. Humerickhouse, R., Lohrbach, K., Li, L., Bosron, W. F., and Dolan, M. E. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res., 60: 1189-1192, 2000.
10. Rivory, L. P., Riou, J. F., Haaz, M. C., Sable, S., Vuilhorgne, M., Commercon, A., Pond, S. M., and Robert, J. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res., 56: 3689-3694, 1996.
11. Dodds, H. M., Haaz, M. C., Riou, J. F., Robert, J., and Rivory, L. P. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J. Pharmacol. Exp. Ther., 286: 578-583, 1998.
12. Guichard, S. M., Morton, C. L., Krull, E. J., Stewart, C. F., Danks, M. K., and Potter, P. M. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. Clin. Cancer Res., 4: 3089-3094, 1998.
13. Cygler, M., Schrag, J. D., Sussman, J. L., Harel, M., Silman, I., Gentry, M. K., and Doctor, B. P. Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases, and related proteins. Protein Sci., 2: 366-382, 1993.
14. Satoh, T., and Hosokawa, M. The mammalian carboxylesterases: from molecules to functions. Annu. Rev. Pharmacol. Toxicol., 38: 257-288, 1998.
15. Sone, T., and Wang, C. Y. Microsomal amidases and carboxylesterases. Comp. Toxicol., 3: 265-281, 1997.
16. Satoh, T., Taylor, P., Bosron, W. F., Sanghani, S. P., Hosokawa, M., and La Du, B. N. Current progress on esterases: from molecular structure to function. Drug Metab. Dispos., 30: 488-493, 2002.
17. Mori, M., Hosokawa, M., Ogasawara, Y., Tsukada, E., and Chiba, K. cDNA cloning, characterization and stable expression of novel human brain carboxylesterase. FEBS Lett., 458: 17-22, 1999.
18. Hennebelle, I., Terret, C., Chatelut, E., Bugat, R., Canal, P., and Guichard, S. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitrophenylacetate converting carboxylesterase activity. Anticancer Drugs, 11: 465-470, 2000.
19. Xie, M., Yang, D., Liu, L., Xue, B., and Yan, B. Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression. Drug Metab. Dispos., 30: 541-547, 2002.
20. Xu, G., Zhang, W., Ma, M. K., and McLeod, H. L. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin. Cancer Res., 8: 2605-2611, 2002.
21. Brzezinski, M. R., Abraham, T. L., Stone, C. L., Dean, R. A., and Bosron, W. F. Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem. Pharmacol., 48: 1747-1755, 1994.
22. Pindel, E. V., Kedishvili, N. Y., Abraham, T. L., Brzezinski, M. R., Zhang, J., Dean, R. A., and Bosron, W. F. Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J. Biol. Chem., 272: 14769-14775, 1997.
23. Dean, R. A., Zhang, J., Brzezinski, M. R., and Bosron, W. F. Tissue distribution of cocaine methyl esterase and ethyl transferase activities: correlation with carboxylesterase protein. J. Pharmacol. Exp. Ther., 275: 965-971, 1995.
24. Fleming, I. D., Cooper, J. S., Henson, D. E., Hutter, R. V. P., Kennedy, B. J., Murphy, G. P., O'Sullivan, B., Sobin, L. H., and Yarbro, J. W. (eds.). AJCC Cancer Staging Manual, Ed. 5, pp. 83-90. Philadelphia: Lippincott, Williams and Wilkins, 1997.
25. Wu, M. H., Yan, B., Humerickhouse, R., and Dolan, M. E. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin. Cancer Res., 8: 2696-2700, 2002.
26. Guichard, S., Terret, C., Hennebelle, I., Lochon, I., Chevreau, P., Fretigny, E., Selves, J., Chatelut, E., Bugat, R., and Canal, P. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br. J. Cancer, 80: 364-370, 1999.
27. Woessner, R. D., Eng, W. K., Hofmann, G. A., Rieman, D. J., McCabe, F. L., Hertzberg, R. P., Mattern, M. R., Tan, K. B., and Johnson, R. K. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol. Res., 4: 481-488, 1992.
28. Chang, J. Y., Dethlefsen, L. A., Barley, L. R., Zhou, B. S., and Cheng, Y. C. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol., 43: 2443-2452, 1992.
29. Santos, A., Zanetta, S., Cresteil, T., Deroussent, A., Pein, F., Raymond, E., Vernillet, L., Risse, M. L., Boige, V., Gouyette, A., and Vassal, G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res., 6: 2012-2020, 2000.
30. Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., and Ratain, M. J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Investig., 101: 847-854, 1998.
31. Salonga, D., Danenberg, K. D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D. D., Lenz, H. J., Leichman, C. G., Leichman, L., Diasio, R. B., and Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res., 6: 1322-1327, 2000.